The present invention determines the expression of the marker gene KIAA1199, relates to an in vitro method of diagnosing chronic obstructive pulmonary disease (COPD). In particular, the invention, DMBT1 optionally a marker gene KIAA1199, TMSB15A, DPP6, SLC51B, NUDT11, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR110, GDF15, RASGRF2, RND1, PLA1A, FGG, CEACAM5, HYAL2, AHRR, CXCL3, CYP1A1, CYP1B1, CYP1A2, CST6, NTRK2, COMP, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 and determines expression of one or more additional marker genes selected from GHRL, It relates to an in vitro diagnostic method of assessing the sensitivity of a subject generation of advanced stage COPD that occurrence of irreversible lung injury is involved. The present invention is directed to a method for the production of a compound of the present invention comprising administering to a patient in need of such treatment KIAA 1199 and optionally DMBT 1, TMSB 15 A, DPP 6, SLC 51 B, NUDT 11, ELF 5, AZGP 1, PRRX 1, AQP 3, SFN, GPR 110, GDF 15, RASGRF 2, RND 1, PLA 1 A, FGG, CEACAM 5, HYAL 2, AHRR, CXCL 3, CYP 1 A 1, CYP1B1, CYP1A2, CST6, NTRK2, COMP, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 and determines expression of one or more additional marker genes selected from GHRL, diagnosing plateau COPD Or in vitro methods of assessing the susceptibility of a subject to the occurrence of stable phase COPD. Furthermore, the invention relates to the use of primers for the transcripts of the marker genes mentioned above in the corresponding in vitro methods, the use of nucleic acid probes for the transcripts of these marker genes, nucleic acid probes for the transcripts of these marker genes And to the use of antibodies against proteins expressed from these marker genes. Determining the expression of a marker gene according to the present invention, also provides in vitro methods of monitoring the progression of COPD.本発明は、マーカー遺伝子KIAA1199の発現を判定する、慢性閉塞性肺疾患(COPD)のインビトロ診断方法に関する。詳細には、本発明は、マーカー遺伝子KIAA1199と場合によりDMBT1、TMSB15
